SGMT
Sagimet Biosciences Inc

2,011
Mkt Cap
$159.35M
Volume
161,396.00
52W High
$11.41
52W Low
$1.73
PE Ratio
-3.26
SGMT Fundamentals
Price
$5.19
Prev Close
$5.14
Open
$5.13
50D MA
$5.73
Beta
0.00
Avg. Volume
650,606.45
EPS (Annual)
-$1.58
P/B
1.50
Rev/Employee
$0.00
$78.44
Loading...
Loading...
News
all
press releases
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings
Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Analysts at HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for Sagimet Biosciences in a report issued on Wednesday, March...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised Sagimet Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·4d ago
News Placeholder
Q1 Earnings Forecast for SGMT Issued By HC Wainwright
Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Sagimet Biosciences in a research report issued on...
MarketBeat·4d ago
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $29.00 price target on shares of Sagimet Biosciences in a research note on Wednesday...
MarketBeat·6d ago
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) Issues Earnings Results
Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of...
MarketBeat·6d ago
News Placeholder
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are covering the firm, Marketbeat.com reports. One...
MarketBeat·10d ago
News Placeholder
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday
Sagimet Biosciences (NASDAQ:SGMT) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 11. (View Earnings Report at...
MarketBeat·14d ago
News Placeholder
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer's 36th Annual Healthcare Life Sciences Conference to outline its strategy around fatty acid synthase (FASN) inhibition...
MarketBeat·16d ago
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) CEO Sells $64,861.36 in Stock
Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) CEO David Happel sold 12,101 shares of the business's stock in a transaction dated Tuesday, February 10th. The stock was sold at an average...
MarketBeat·1mo ago
News Placeholder
David Happel Sells 12,101 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock
Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) CEO David Happel sold 12,101 shares of the business's stock in a transaction dated Tuesday, February 10th. The shares were sold at an average...
MarketBeat·1mo ago
<
1
2
...
>

Latest SGMT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.